Mayo KH - Search Results

1

Dynamic contrast-enhanced magnetic resonance imaging at 1.5 Tesla with gadopentetate dimeglumine to assess the angiostatic effects of anginex in mice.

de Lussanet QG, Beets-Tan RG, Backes WH, van der Schaft DW, van Engelshoven JM, Mayo KH, Griffioen AW. de Lussanet QG, et al. Among authors: mayo kh. Eur J Cancer. 2004 May;40(8):1262-8. doi: 10.1016/j.ejca.2004.01.020. Eur J Cancer. 2004. PMID: 15110892 Free article.

2

The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models.

van der Schaft DW, Dings RP, de Lussanet QG, van Eijk LI, Nap AW, Beets-Tan RG, Bouma-Ter Steege JC, Wagstaff J, Mayo KH, Griffioen AW. van der Schaft DW, et al. Among authors: mayo kh. FASEB J. 2002 Dec;16(14):1991-3. doi: 10.1096/fj.02-0509fje. Epub 2002 Oct 18. FASEB J. 2002. PMID: 12397082

3

Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells.

Dings RP, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Dings RP, et al. Among authors: mayo kh. Int J Cancer. 2005 Jun 10;115(2):312-9. doi: 10.1002/ijc.20850. Int J Cancer. 2005. PMID: 15688384

4

Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane.

Nap AW, Dunselman GA, Griffioen AW, Mayo KH, Evers JL, Groothuis PG. Nap AW, et al. Among authors: mayo kh. Fertil Steril. 2005 Mar;83(3):793-5. doi: 10.1016/j.fertnstert.2004.06.080. Fertil Steril. 2005. PMID: 15749522 Free article.

5

Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein.

Brandwijk RJ, Nesmelova I, Dings RP, Mayo KH, Thijssen VL, Griffioen AW. Brandwijk RJ, et al. Among authors: mayo kh. Biochem Biophys Res Commun. 2005 Aug 12;333(4):1261-8. doi: 10.1016/j.bbrc.2005.06.029. Biochem Biophys Res Commun. 2005. PMID: 15979575

6

Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.

Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JC, Griffioen AW. Dirkx AE, et al. Among authors: mayo kh. FASEB J. 2006 Apr;20(6):621-30. doi: 10.1096/fj.05-4493com. FASEB J. 2006. PMID: 16581970

7

Anti-angiogenesis and anti-tumor activity of recombinant anginex.

Brandwijk RJ, Dings RP, van der Linden E, Mayo KH, Thijssen VL, Griffioen AW. Brandwijk RJ, et al. Among authors: mayo kh. Biochem Biophys Res Commun. 2006 Oct 27;349(3):1073-8. doi: 10.1016/j.bbrc.2006.08.154. Epub 2006 Sep 5. Biochem Biophys Res Commun. 2006. PMID: 16970922

8

Early in vivo assessment of angiostatic therapy efficacy by molecular MRI.

Mulder WJ, van der Schaft DW, Hautvast PA, Strijkers GJ, Koning GA, Storm G, Mayo KH, Griffioen AW, Nicolay K. Mulder WJ, et al. Among authors: mayo kh. FASEB J. 2007 Feb;21(2):378-83. doi: 10.1096/fj.06-6791com. Epub 2007 Jan 3. FASEB J. 2007. PMID: 17202248

9

Anginex-conjugated liposomes for targeting of angiogenic endothelial cells.

Brandwijk RJ, Mulder WJ, Nicolay K, Mayo KH, Thijssen VL, Griffioen AW. Brandwijk RJ, et al. Among authors: mayo kh. Bioconjug Chem. 2007 May-Jun;18(3):785-90. doi: 10.1021/bc060316h. Epub 2007 Mar 23. Bioconjug Chem. 2007. PMID: 17378601

10

Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango.

Thijssen VL, van Beijnum JR, Mayo KH, Griffioen AW. Thijssen VL, et al. Among authors: mayo kh. Curr Pharm Des. 2007;13(35):3576-83. doi: 10.2174/138161207782794121. Curr Pharm Des. 2007. PMID: 18220794 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

281 results

Search Page

Filters